Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCOLN2 | Q8IZK6 | 1/20 | 0.37 |
| ▸ | MCOLN1 | Q9GZU1 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 14/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4290038 | 0.83 | ALDH1A1 (0.37) | MCOLN2MCOLN1CNR1GAAALDH1A1 | |
| SCHEMBL4285705 | 0.79 | ALDH1A1 (0.40) | CNR1GAAALDH1A1TSHR | |
| SCHEMBL4292738 | 0.79 | ALDH1A1 (0.40) | CNR1GAAALDH1A1TSHR | |
| SCHEMBL4293883 | 0.79 | CNR1 (0.36) | CNR1ALDH1A1TSHR | |
| SCHEMBL4286036 | 0.78 | CNR1 (0.37) | CNR1GAAALDH1A1TSHR | |
| SCHEMBL4281165 | 0.78 | HCAR1 (0.43) | CNR1ALDH1A1TSHR | |
| SCHEMBL4284004 | 0.78 | FAAH (0.40) | MCOLN2MCOLN1CNR1ALDH1A1TSHR | |
| SCHEMBL4788333 | 0.77 | HCAR1 (0.44) | CNR1GAATSHR | |
| SCHEMBL4788338 | 0.77 | HCAR1 (0.44) | CNR1GAATSHR | |
| SCHEMBL4788332 | 0.77 | HCAR1 (0.44) | CNR1GAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | MCOLN2 4526/4885MCOLN1 4291/4885CNR1 3488/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | MCOLN2 4526/4885MCOLN1 4291/4885CNR1 3488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.